Erbitux Approved as First-Line Treatment

The FDA has approved Erbitux™ (cetuximab) in combination with FOLFIRI for first-line treatment of patients with metastatic colorectal cancer whose tumors have a wild-type (WT) KRAS gene.  Erbitux was first approved in 2004 for patients whose cancer was not responding to…  Read More

FDA Takes Action on Two Critical Cancer Drugs in Shortage

FDA Commissioner Margaret Hamburg announced yesterday during a teleconference that the FDA has arranged to meet critical needs for methotrexate and Doxil® (doxorubicin). FDA has approved temporarily importing Lipodox, which has the same active ingredient — doxorubicin — and the…  Read More

The White House Addresses the Drug Shortage Issue

President Barack Obama signed an Executive Order yesterday addressing the drug shortage issue. As we have reported extensively on www.FightColorectalCancer.org, the current drug shortages have impacted colorectal cancer patients who have been unable to get 5-FU, leucovorin or on occasion,…  Read More